Literature DB >> 2162190

Ocular herpes simplex virus infections: reduced sensitivity to acyclovir in primary disease.

S J Charles1, J J Gray.   

Abstract

Forty isolates of herpes simplex virus (HSV) obtained from ocular herpetic infections were assayed for their sensitivity to five antiviral agents. There were wide ranges of sensitivity to foscarnet, idoxuridine, and vidarabine, but the majority were sensitive to acyclovir and ganciclovir. Reduced sensitivity to acyclovir was seen in four isolates, all of which were from primary infections acquired in the community and without a previous history of treatment with antiviral drugs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2162190      PMCID: PMC1042100          DOI: 10.1136/bjo.74.5.286

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  12 in total

1.  Susceptibility to acyclovir of herpes simplex virus: emergence of resistance in patients with lymphoid and myeloid neoplasia.

Authors:  J J Gray; T G Wreghitt; T P Baglin
Journal:  J Infect       Date:  1989-07       Impact factor: 6.072

2.  9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group.

Authors:  H J Schaeffer; L Beauchamp; P de Miranda; G B Elion; D J Bauer; P Collins
Journal:  Nature       Date:  1978-04-13       Impact factor: 49.962

3.  Antiviral activity of 9-beta-D-arabinofuranosyladenine. I. Cell culture studies.

Authors:  F A Miller; G J Dixon; J Ehrlich; B J Sloan; I W McLean
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1968

4.  Intraocular antiviral penetration.

Authors:  R H Poirier; J D Kingham; P de Miranda; M Annel
Journal:  Arch Ophthalmol       Date:  1982-12

5.  Oral acyclovir (Zovirax) in herpes simplex dendritic corneal ulceration.

Authors:  L M Collum; P McGettrick; J Akhtar; J Lavin; P J Rees
Journal:  Br J Ophthalmol       Date:  1986-06       Impact factor: 4.638

6.  Isolation and characterization of acyclovir-resistant mutants of herpes simplex virus.

Authors:  H J Field; G Darby; P Wildy
Journal:  J Gen Virol       Date:  1980-07       Impact factor: 3.891

7.  Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci.

Authors:  L E Schnipper; C S Crumpacker
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

8.  Resistance of peripheral autonomic neurons to in vivo productive infection by herpes simplex virus mutants deficient in thymidine kinase activity.

Authors:  R W Price; A Khan
Journal:  Infect Immun       Date:  1981-11       Impact factor: 3.441

9.  Metabolism of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, a new anti-herpes virus compound, in herpes simplex virus-infected cells.

Authors:  Y C Cheng; S P Grill; G E Dutschman; K Nakayama; K F Bastow
Journal:  J Biol Chem       Date:  1983-10-25       Impact factor: 5.157

Review 10.  A perspective on resistance to acyclovir in herpes simplex virus.

Authors:  H J Field
Journal:  J Antimicrob Chemother       Date:  1983-09       Impact factor: 5.790

View more
  4 in total

1.  Clinical characteristics of acyclovir-resistant herpetic keratitis and experimental studies of isolates.

Authors:  Y F Yao; Y Inoue; T Kase; Y Uchihori; Y Mori; Y Ohashi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

Review 2.  Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  A J Wagstaff; D Faulds; K L Goa
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

3.  Acute Herpetic Keratitis: What is the Role for Ganciclovir Ophthalmic Gel?

Authors:  Afsun Sahin; Pedram Hamrah
Journal:  Ophthalmol Eye Dis       Date:  2012-04-19

Review 4.  Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications.

Authors:  Timothy Y Chou; Bennett Y Hong
Journal:  Ther Clin Risk Manag       Date:  2014-08-20       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.